Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Heparin Crisis Spurs Changes In FDA Emergency Response Policies

Executive Summary

Internal and external evaluations of FDA’s handling of the heparin contamination crisis two years ago have led to changes in the agency’s emergency response strategy and a new policy on emergency collaborations with outside experts.

You may also be interested in...



Heparin Crisis Leads To New FDA Policy On Consulting Outside Experts

A Government Accountability Office report criticizing FDA's retention of outside experts on heparin contamination spurs disclosure and conflict-of-interest screening policies for emergency situations.

Elections Reshape FDA Oversight Scene On Capitol Hill

The Republican takeover in the House shuffles the leadership in committees crucial to the dietary supplement and OTC drug industries while likely setting the stage for cuts to FDA funding.

Amphastar Lawsuit Over Heparin Shipments Suggests Lovenox ANDA Approval May Be Far Off

Allegations in Amphastar Pharmaceuticals’ lawsuit over FDA detention of heparin raw ingredient shipments suggest approval of its enoxaparin ANDA, the generic of Sanofi-Aventis’ low-molecular weight heparin Lovenox, is far from imminent.

Related Content

Topics

UsernamePublicRestriction

Register

PS052833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel